Treatment of CMV Retinitis

Paul R. Skolnik; Susan W. Cox; Britta Wahren; G. Deray; C. Katlama; C. Jacobs; David M. Bachman; Matthew D. Davis; Douglas A. Jabs; Curtis L. Meinert; Richard L. Mowery

doi:10.1056/NEJM199206183262513

Treatment of CMV Retinitis

Paul R. Skolnik
, Susan W. Cox
, Britta Wahren
, G. Deray
, C. Katlama
, C. Jacobs
, David M. Bachman
, Matthew D. Davis
, Douglas A. Jabs
, Curtis L. Meinert
, Richard L. Mowery

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Abstract

To the Editor: The study (Jan. 23 issue)¹ of the comparative efficacy of foscarnet and ganciclovir for the treatment of cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS) provides important information. On October 17, 1991, the Department of Health and Human Services issued a clinical alert from the National Institutes of Health about this study. The alert was widely disseminated. It stated that patients who received foscarnet lived an average of four months longer than those who received ganciclovir. An immediate question this raises is the effect of concomitant therapy with zidovudine. The clinical alert stated…

Original language	English
Pages (from-to)	1701-1703
Number of pages	3
Journal	New England Journal of Medicine
Volume	326
Issue number	25
DOIs	https://doi.org/10.1056/NEJM199206183262513
State	Published - 18 Jun 1992
Externally published	Yes

Access to Document

10.1056/NEJM199206183262513

Cite this

@article{a4c0b2afd7474bbda56d561e8651bd49,

title = "Treatment of CMV Retinitis",

abstract = "To the Editor: The study (Jan. 23 issue)1 of the comparative efficacy of foscarnet and ganciclovir for the treatment of cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS) provides important information. On October 17, 1991, the Department of Health and Human Services issued a clinical alert from the National Institutes of Health about this study. The alert was widely disseminated. It stated that patients who received foscarnet lived an average of four months longer than those who received ganciclovir. An immediate question this raises is the effect of concomitant therapy with zidovudine. The clinical alert stated…",

author = "Skolnik, \{Paul R.\} and Cox, \{Susan W.\} and Britta Wahren and G. Deray and C. Katlama and C. Jacobs and Bachman, \{David M.\} and Davis, \{Matthew D.\} and Jabs, \{Douglas A.\} and Meinert, \{Curtis L.\} and Mowery, \{Richard L.\}",

year = "1992",

month = jun,

day = "18",

doi = "10.1056/NEJM199206183262513",

language = "English",

volume = "326",

pages = "1701--1703",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "25",

}

TY - JOUR

T1 - Treatment of CMV Retinitis

AU - Skolnik, Paul R.

AU - Cox, Susan W.

AU - Wahren, Britta

AU - Deray, G.

AU - Katlama, C.

AU - Jacobs, C.

AU - Bachman, David M.

AU - Davis, Matthew D.

AU - Jabs, Douglas A.

AU - Meinert, Curtis L.

AU - Mowery, Richard L.

PY - 1992/6/18

Y1 - 1992/6/18

N2 - To the Editor: The study (Jan. 23 issue)1 of the comparative efficacy of foscarnet and ganciclovir for the treatment of cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS) provides important information. On October 17, 1991, the Department of Health and Human Services issued a clinical alert from the National Institutes of Health about this study. The alert was widely disseminated. It stated that patients who received foscarnet lived an average of four months longer than those who received ganciclovir. An immediate question this raises is the effect of concomitant therapy with zidovudine. The clinical alert stated…

AB - To the Editor: The study (Jan. 23 issue)1 of the comparative efficacy of foscarnet and ganciclovir for the treatment of cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS) provides important information. On October 17, 1991, the Department of Health and Human Services issued a clinical alert from the National Institutes of Health about this study. The alert was widely disseminated. It stated that patients who received foscarnet lived an average of four months longer than those who received ganciclovir. An immediate question this raises is the effect of concomitant therapy with zidovudine. The clinical alert stated…

UR - https://www.scopus.com/pages/publications/1642463966

U2 - 10.1056/NEJM199206183262513

DO - 10.1056/NEJM199206183262513

M3 - Letter

C2 - 1534145

AN - SCOPUS:1642463966

SN - 0028-4793

VL - 326

SP - 1701

EP - 1703

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 25

ER -

Treatment of CMV Retinitis

Abstract

Access to Document

Fingerprint

Cite this